NCT04865445

Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)

A Phase 1 Open-Label Study to Evaluate the Interaction Potential Between AT 527 and Midazolam in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Atea Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Drug-drug interaction study of midazolam and AT-527 (R07496998)

Conditions

• Healthy Volunteer Study

Interventions

Type	Name	Description
DRUG	AT-527 550 mg + midazolam	Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening. Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening. Other Names: AT-527 is also know as R07496998
DRUG	AT-527 550 mg + midazolam	Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening. Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening. Other Names: AT-527 is also know as R07496998

Timeline

• Start date: 2021-04-22
• Primary completion: 2021-05-15
• Completion: 2021-05-15
• First posted: 2021-04-29
• Last updated: 2021-07-29

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study